Researchers at Yale School of Medicine have identified persistent microclots in the cerebral vasculature as a primary mechanism behind long COVID brain fog, offering both an explanation and potential treatment pathway for millions of sufferers.
Study Details
Using advanced fluorescence microscopy on blood samples from 840 long COVID patients, the team found anomalous fibrin-amyloid microclots in 78% of patients reporting cognitive symptoms.
- Microclots trap inflammatory molecules that impair oxygen delivery to brain tissue
- Clots persist for months after acute infection, resisting normal fibrinolysis
- Triple anticoagulant therapy dissolved microclots in 82% of treated patients within 8 weeks
- Cognitive scores improved 45% in treatment group versus 12% in placebo
Treatment Implications
The findings have prompted the NIH to fast-track a Phase 3 clinical trial of targeted anticoagulant therapy for long COVID cognitive symptoms. An estimated 6 million Americans currently experience brain fog as their primary long COVID symptom, many unable to return to work or school at full capacity.
